MAPT and Alzheimer disease: Thus, despite the hurdles created by the need to use invasive procedures to deliver these therapeutics and the difficulties in assessing target engagement in human trials, there is a strong rationale for pursuing gene-silencing therapies for tau in FTD and possibly AD.